High prevalence of blindness and ocular complications in leprosy patients

Article

Data presented in an advance on-line publication of the journal Eye has shown a high occurrence of ocular conditions in UK leprosy patients.

Data presented in an advance on-line publication of the journal Eye has shown a high occurrence of ocular conditions in UK leprosy patients.

Dr A. Malik et al., Moorfields Eye Hospital, London, UK, conducted an observational, prospective study on 126 consecutive leprosy patients. The participants were examined during their ophthalmic visits.

Of the 126 patients, 18 presented with blindness in one eye and 5 patients were blind in both eyes. The findings demonstrated that 96 patients had a visual acuity of 6/18, 28 patients had a leprosy complication that severely affects sight and 65 patients had a form of ocular complication such as lagophthalmos, severe corneal or iris disease.

The most frequent ocular complications were impaired lid closure, impaired corneal sensation, mild corneal opacity, cataract and iris atrophy. Increasing age was linked to impaired lid closure and vision less than 6/18 was linked to impaired corneal sensation.

The results revealed that one in five leprosy patients suffered from some form of ocular complication or blindness. The study advises health professionals to increase awareness on the implications of leprosy and the risk of sight-threatening ocular complications.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.